Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Certolizumab Pegol in Active RA
NCT04740814Phase 1Completed
- Sponsor
- UCB
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoints: Minimum Observed Plasma Concentration at Week 12 and Area Under the Concentration-time Curve Over One Dosing Interval at Week 12. Started Feb 2021; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04740814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740814.